Cardiovascular Business
FDA Recalls Supplement Over Risk of Heart Attack or Stroke
Doximity
The Art and Science of Medicine With Peer-Reviewed AI
Journal of Cardiac Failure
Empagliflozin vs. Dapagliflozin in Heart Failure: A Target Trial Emulation
KevinMD
Are Mild Hypertension Guidelines Driven by Pharma Ties?
Op-Med
Medicine’s Most Dangerous Conflict of Interest
Journal of the Society for Cardiovascular Angiography & Interventions
Comparing Different SCAI SHOCK Stage Classification Systems in Patients with Cardiogenic Shock
Cardionerds
Anti-Arrhythmic Drugs in the Management of Atrial Arrhythmias with Dr. Andrew Epstein
Journal of the American College of Cardiology
Inaugural ACC Report: Cardiovascular Statistics in the United States, 2026
You're receiving this digest based on your specialty. Did we get it wrong? Update preferences here.
Download for iOS or Android.
Doximity.com • 500 3rd Street, Suite 510 • San Francisco, CA 94107
Unsubscribe from Doximity | Specialty News • Terms of Service • Privacy Policy
UUID: 62baf427-4825-471f-b2fb-87f7995d4887